

# BuyersStrike!

## It Was Dark Over Westphalia

### Quick Take: What Craziness is Cytodyn Pivoting to Today? (CYDY)

That was fast. Just last Friday we predicted everyone's favorite reverse-merger pink sheet Coronacraper, **Cytodyn (CYDY)** would need to spin a new yarn for its legions of rabid retail fans. With the likelihood of the delusional fantasy of an EUA for treating severe-to-critical Covid patients dropping to virtually 0% (read why [here \(https://buyersstrike.wordpress.com/2020/10/23/quick-take-what-cytodelusion-actually-died-last-night-cydy/\)](https://buyersstrike.wordpress.com/2020/10/23/quick-take-what-cytodelusion-actually-died-last-night-cydy/)), the company has wasted no time in pivoting to the next nonsense. They have just issued a press release that could be the dictionary definition of the "post hoc ergo propter hoc" fallacy:

## Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke

October 26, 2020 6:00am EDT

 Download as PDF

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- **CytoDyn Inc. (OTC.QB: CYDY)**, ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today two patients have demonstrated noticeable signs of improvement following treatment with leronlimab (PRO 140) in helping their recovery from stroke.

The most recent stroke patient, a physician in Mississippi, requested leronlimab, which was administered to him under Mississippi's recently expanded "Right to Try" statute. The physician's son, commenting on his father, stated, "He is doing good. Yesterday, he received his second treatment. He said he has been feeling better, and he thinks it is working. He said parts of his body and face that have been numb are starting to change/wake up."

(<https://buyersstrike.files.wordpress.com/2020/10/image-3.png>).

And the first patient, from prior CONFERENCE calls we know she is none other than **The NaDDir's\* Mother-in-Law**:

A second stroke patient was receiving treatment with leronlimab as part of her therapy for breast cancer. The treating physician noted her partial paralysis was mitigated relatively quickly, which may have been causally related to the posited role of CCR5 in stroke.

(<https://buyersstrike.files.wordpress.com/2020/10/image-4.png>).

Notice **what is missing** from both patient anecdotes?

What were the **severity of the strokes** (NIHSS scores or 6S scores)? What were the **quantitative levels of improvement** in something recognized, like the 10m walk test? Only vague nonsense to keep retail investors glued in their seats.

The last time **Cytodyn** issued such ridiculous anecdotal bs was the infamous breast cancer patient patient press release from the 12th of March that was quickly deleted from their website, but captured for eternity here:

CytoDyn's First mTNBC Patient in Phase 1b/2 is in Remission and Oncologist Ordered Termination of Treatment with Carboplatin (chemotherapy drug) and Remains on Leronlimab Only as Monotherapy; Patient's Testimony about Her Condition After Nearly 6 Months of Leronlimab Treatment is Very Strong

At the Recommendation of the FDA, CytoDyn Will Request a Preliminary Breakthrough Therapy Designation Meeting

VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- **CytoDyn Inc. (OTC.QB: CYDY)**, ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA recommended that the Company request a preliminary Breakthrough Therapy designation meeting. Meanwhile, the Company continues reporting very positive data for its mTNBC and MBC patients.

[https://buyersstrike.files.wordpress.com/2020/10/image\\_2020-10-](https://buyersstrike.files.wordpress.com/2020/10/image_2020-10-05_125119.png)

[05\\_125119.png](#)

The relentless hyping of bs anecdotes, and the intentional withholding of actual, complete, trial data, is a hallmark of bioscams. Roughly 800,000 Americans have a stroke each year, Cytodyn is attempting to spin two of their stories into fool's gold.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS; ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Posted in [Bad Directors](#), [Bio-Dreck](#), [Bucket Shops](#), [CoronaCrap](#), [Reverse Mergers](#) on [October 26, 2020](#) by [BuyersStrike!](#). [Leave a comment](#)  
This site uses Akismet to reduce spam. [Learn how your comment data is processed.](#)

[CREATE A FREE WEBSITE OR BLOG AT WORDPRESS.COM.](#)